This Plain Language Summary of Publication from Future Oncology describes a study called MajesTEC-1 which looked at how effective a drug called teclistamab is in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells.

Read the full article here.

The original article on which this Plain Language Summary is based is titled ‘Teclistamab in Relapsed or Refractory Multiple Myeloma’ and was published in The New England Journal of Medicine. Read the original article here.